While Avadel Pharmaceuticals plc has underperformed by -1.59%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVDL fell by -11.61%, with highs and lows ranging from $17.30 to $6.38, whereas the simple moving average fell by -8.08% in the last 200 days.
On February 11, 2025, Deutsche Bank started tracking Avadel Pharmaceuticals plc (NASDAQ: AVDL) recommending Buy. A report published by Rodman & Renshaw on June 12, 2024, Initiated its previous ‘Buy’ rating for AVDL. Oppenheimer also reiterated AVDL shares as ‘Outperform’, quoting a target price of $29 on the company’s shares in a report dated March 05, 2024. Needham Reiterated the rating as Buy on March 05, 2024, but set its price target from $20 to $22. H.C. Wainwright resumed its ‘Buy’ rating for AVDL, as published in its report on March 05, 2024. UBS’s report from February 06, 2024 suggests a price prediction of $21 for AVDL shares, giving the stock a ‘Buy’ rating. Jefferies also rated the stock as ‘Buy’.
Analysis of Avadel Pharmaceuticals plc (AVDL)
Further, the quarter-over-quarter increase in sales is 93.21%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Avadel Pharmaceuticals plc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -34.65% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.33, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and AVDL is recording an average volume of 1.34M. On a monthly basis, the volatility of the stock is set at 4.59%, whereas on a weekly basis, it is put at 4.77%, with a loss of -0.32% over the past seven days. Furthermore, long-term investors anticipate a median target price of $16.57, showing growth from the present price of $9.29, which can serve as yet another indication of whether AVDL is worth investing in or should be passed over.
How Do You Analyze Avadel Pharmaceuticals plc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.65%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 77.00% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AVDL shares are owned by institutional investors to the tune of 77.00% at present.
